Researchers Develop a Drugs for Slimy Bugs to Fight Against Staphylococcus Infections

Eradicating deadly staphylococcus using a new breed of antibiotics has revealed promising leads to analysis launched by QUT, to assist overcome one of many biggest modern medical challenges.

The bacteria connect to medical devices together with catheters, artificial joints, implants, and patients’ burns and wounds, establishing bacterial biofilms, a number one explanation for failing antibiotic therapies, and chronic infections.

QUT researchers might have developed hybrid antibiotics that are designed to penetrate the slimy shield protecting invasive golden staph (Staphylococcus aureus) infections. Led by Associate Professor Makrina Totsika and Ph.D. student Anthony Verderosa, the research has been revealed in high infectious diseases journal Antimicrobial Agents and Chemotherapy.

The research discovered hybrid antibiotics worked effectively by destroying Staph biofilms grown within the lab. Associate Professor Totsika stated nearly all of the infections, even those not related to an implanted medical device, contain biofilms in some way, so the potential for this medicine is vast.

Hospital-acquired infections and increasing resistance to antibiotics have challenged medical researchers to seek out and check novel antimicrobial agents, including alternate options to antibiotics.

The World Health Organisation has recognized antibiotic-resistant pathogens as one of many “biggest threats to global health today.”

Associate Professor Totsika mentioned there was scope to use the past research drugs, agriculture, biotechnology, and different industries. QUT Vice-Chancellor’s Research Fellowship and her analysis are supported by grants from the National Health and Medical Research Council and the Australian Research Council.

Researchers involved in growing the hybrid antibiotics, came collectively from QUT’s An infection and Immunity Research Program in addition to the Molecular Design and Synthesis Chemistry program.